Journal
EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 9, Issue 8, Pages 1069-1080Publisher
TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.11.83
Keywords
atherogenic; dyslipidemia; hyperlipidemia; lipid-lowering drugs; metabolic syndrome; obesity; statins; weight loss surgery
Categories
Ask authors/readers for more resources
Obesity is the most common cause of secondary hyperlipidemia. Atherogenic dyslipidemia refers to elevated triglycerides, low HDL-cholesterol and small dense LDL associated with visceral obesity and metabolic syndrome. Obesity may also be associated with isolated low HDL-cholesterol or high triglycerides and postprandial hyperlipidemia. While some obese patients have high LDL cholesterol concentrations, obesity has a more pronounced effect on other atherogenic lipids and lipoproteins. Obesity may aggravate familial lipid disorders. Lipid disorders in obesity are responsive to weight loss, pharmacotherapy and weight loss surgery. Statins are the lipid-lowering drug of choice, together with lifestyle change. Hard clinical end point data to support combinations of statins with other drugs is lacking. After weight loss surgery, the absolute risk of cardiovascular disease should be reassessed, but tools to facilitate risk assessment need to be developed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available